Company intelligence / Profile preview
Contera Pharma
Hørsholm, Hovedstaden, Denmarkconterapharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Contera Pharma A/S is a Danish clinical-stage biotech company developing innovative therapies for neurological disorders. The company has focused on proprietary treatments targeting movement complications in Parkinson's disease, such as dyskinesia and morning akinesia. It leverages a proprietary platform to address unmet needs within the central nervous system therapeutic area. As of May 2024, some clinical programs have faced setbacks but the company remains active with ongoing preclinical development.
- Therapeutic areas
- Neurology
- Modalities
- Small moleculesProprietary drug delivery systems
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
License to formulation technology with BDD Pharma, UK; partnerships/collaborations within biotech/pharma industry generally referenced but specifics limited.
Beyond the preview
Go deeper on Contera Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Contera Pharma.